{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T08:11:29Z","timestamp":1778227889141,"version":"3.51.4"},"reference-count":57,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2027,2,3]],"date-time":"2027-02-03T00:00:00Z","timestamp":1801612800000},"content-version":"am","delay-in-days":367,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000019","name":"National Hemophilia Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000019","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004339","name":"Sanofi","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004339","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["1OT3HL147154"],"award-info":[{"award-number":["1OT3HL147154"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["1OT3HL142481-01"],"award-info":[{"award-number":["1OT3HL142481-01"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["1OT3HL142479-01"],"award-info":[{"award-number":["1OT3HL142479-01"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["1OT3HL142480-01"],"award-info":[{"award-number":["1OT3HL142480-01"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["1OT3HL142478-01"],"award-info":[{"award-number":["1OT3HL142478-01"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007188","name":"Uniformed Services University of the Health Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007188","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100011918","name":"Hemophilia of Georgia","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011918","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100017540","name":"National Heart Lung and Blood Institute Division of Intramural Research","doi-asserted-by":"publisher","award":["R01-HL-130448"],"award-info":[{"award-number":["R01-HL-130448"]}],"id":[{"id":"10.13039\/100017540","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000050","name":"National Heart, Lung, and Blood Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jthjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Thrombosis and Haemostasis"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1016\/j.jtha.2025.08.040","type":"journal-article","created":{"date-parts":[[2026,2,3]],"date-time":"2026-02-03T20:37:25Z","timestamp":1770151045000},"page":"443-457","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Human leukocyte antigen alleles associated with inhibitor development in severe hemophilia A: analysis of the \u201cMy Life, Our Future\u201d hemophilia A cohort"],"prefix":"10.1016","volume":"24","author":[{"given":"Sara","family":"Contente","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anwar E.","family":"Ahmed","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Barbara A.","family":"Konkle","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jill M.","family":"Johnsen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew","family":"Frank","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6837-6133","authenticated-orcid":false,"given":"Kathleen P.","family":"Pratt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jtha.2025.08.040_bib1","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1182\/bloodadvances.2016002923","article-title":"Novel approach to genetic analysis and results in 3000 hemophilia patients enrolled in the My Life, Our Future initiative","volume":"1","author":"Johnsen","year":"2017","journal-title":"Blood Adv"},{"issue":"Suppl 6","key":"10.1016\/j.jtha.2025.08.040_bib2","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1111\/hae.13506","article-title":"My Life Our Future p. Genotypes, phenotypes and whole genome sequence: approaches from the My Life Our Future haemophilia project","volume":"24","author":"Konkle","year":"2018","journal-title":"Haemophilia"},{"key":"10.1016\/j.jtha.2025.08.040_bib3","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1016\/j.jtha.2022.12.017","article-title":"Race, ethnicity, F8 variants, and inhibitor risk: analysis of the \u201cMy Life Our Future\u201d hemophilia A database","volume":"21","author":"Ahmed","year":"2023","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.jtha.2025.08.040_bib4","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1056\/NEJM199302183280701","article-title":"Recombinant factor VIII for the treatment of previously untreated patients with hemophilia A. Safety, efficacy, and development of inhibitors. Kogenate Previously Untreated Patient Study Group","volume":"328","author":"Lusher","year":"1993","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtha.2025.08.040_bib5","doi-asserted-by":"crossref","first-page":"2022","DOI":"10.1111\/jth.15805","article-title":"Results of genetic analysis of 11 341 participants enrolled in the My Life, Our Future hemophilia genotyping initiative in the United States","volume":"20","author":"Johnsen","year":"2022","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.jtha.2025.08.040_bib6","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.thromres.2018.05.027","article-title":"Risk factors for inhibitor development in severe hemophilia a","volume":"168","author":"Garagiola","year":"2018","journal-title":"Thromb Res"},{"key":"10.1016\/j.jtha.2025.08.040_bib7","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1111\/j.1365-2516.2009.02058.x","article-title":"Risk factors for inhibitor formation in haemophilia: a prevalent case-control study","volume":"15","author":"Ragni","year":"2009","journal-title":"Haemophilia"},{"key":"10.1016\/j.jtha.2025.08.040_bib8","doi-asserted-by":"crossref","first-page":"2922","DOI":"10.1182\/blood-2011-09-379453","article-title":"F8 gene mutation type and inhibitor development in patients with severe hemophilia A: systematic review and meta-analysis","volume":"119","author":"Gouw","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2025.08.040_bib9","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1038\/nm.3270","article-title":"Endogenous factor VIII synthesis from the intron 22-inverted F8 locus may modulate the immunogenicity of replacement therapy for hemophilia A","volume":"19","author":"Pandey","year":"2013","journal-title":"Nat Med"},{"key":"10.1016\/j.jtha.2025.08.040_bib10","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1182\/blood-2013-12-530113","article-title":"The intron-22-inverted F8 locus permits factor VIII synthesis: explanation for low inhibitor risk and a role for pharmacogenomics","volume":"125","author":"Sauna","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2025.08.040_bib11","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1038\/ng1193-236","article-title":"Inversions disrupting the factor VIII gene are a common cause of severe haemophilia A","volume":"5","author":"Lakich","year":"1993","journal-title":"Nat Genet"},{"key":"10.1016\/j.jtha.2025.08.040_bib12","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1093\/hmg\/2.11.1773","article-title":"Characteristic mRNA abnormality found in half the patients with severe haemophilia A is due to large DNA inversions","volume":"2","author":"Naylor","year":"1993","journal-title":"Hum Mol Genet"},{"key":"10.1016\/j.jtha.2025.08.040_bib13","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1055\/s-0038-1655944","article-title":"HLA class II profile: a weak determinant of factor VIII inhibitor development in severe haemophilia A. UKHCDO Inhibitor Working Party","volume":"77","author":"Hay","year":"1997","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.jtha.2025.08.040_bib14","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0218258","article-title":"Risk stratification integrating genetic data for factor VIII inhibitor development in patients with severe hemophilia A","volume":"14","author":"Bachelet","year":"2019","journal-title":"PLoS One"},{"key":"10.1016\/j.jtha.2025.08.040_bib15","article-title":"HLA Variants and Inhibitor Development in Hemophilia A: a retrospective case-controlled study using the ATHNdataset","volume":"8","author":"McGill","year":"2021","journal-title":"Front Med (Lausanne)"},{"key":"10.1016\/j.jtha.2025.08.040_bib16","article-title":"Genome-Wide Association Study and gene-based analysis of participants with hemophilia A and inhibitors in the \u201cMy Life, Our Future\u201d research repository","volume":"9","author":"Lessard","year":"2022","journal-title":"Front Med (Lausanne)"},{"key":"10.1016\/j.jtha.2025.08.040_bib17","doi-asserted-by":"crossref","first-page":"3713","DOI":"10.1182\/blood-2006-06-026104","article-title":"A sequence variation scan of the coagulation factor VIII (FVIII) structural gene and associations with plasma FVIII activity levels","volume":"109","author":"Viel","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2025.08.040_bib18","doi-asserted-by":"crossref","first-page":"1618","DOI":"10.1056\/NEJMoa075760","article-title":"Inhibitors of factor VIII in black patients with hemophilia","volume":"360","author":"Viel","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtha.2025.08.040_bib19","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1182\/bloodadvances.2017013482","article-title":"FVIII proteins with a modified immunodominant T-cell epitope exhibit reduced immunogenicity and normal FVIII activity","volume":"2","author":"Ettinger","year":"2018","journal-title":"Blood Adv"},{"key":"10.1016\/j.jtha.2025.08.040_bib20","doi-asserted-by":"crossref","first-page":"S5","DOI":"10.1055\/s-0037-1616867","article-title":"Regulatory T cells and their potential for tolerance induction in haemophilia A patients","volume":"36","author":"Schmidt","year":"2016","journal-title":"Hamostaseologie"},{"key":"10.1016\/j.jtha.2025.08.040_bib21","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1182\/blood-2016-07-727834","article-title":"FVIII-specific human chimeric antigen receptor T-regulatory cells suppress T- and B-cell responses to FVIII","volume":"129","author":"Yoon","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2025.08.040_bib22","doi-asserted-by":"crossref","DOI":"10.1172\/JCI159925","article-title":"Immune tolerance against infused FVIII in hemophilia A is mediated by PD-L1+ Tregs","volume":"132","author":"Becker-Gotot","year":"2022","journal-title":"J Clin Invest"},{"key":"10.1016\/j.jtha.2025.08.040_bib23","doi-asserted-by":"crossref","first-page":"4394","DOI":"10.1093\/bioinformatics\/btz235","article-title":"HLA\u2217LA-HLA typing from linearly projected graph alignments","volume":"35","author":"Dilthey","year":"2019","journal-title":"Bioinformatics"},{"key":"10.1016\/j.jtha.2025.08.040_bib24","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1038\/nbt.3820","article-title":"Nextflow enables reproducible computational workflows","volume":"35","author":"Di Tommaso","year":"2017","journal-title":"Nat Biotechnol"},{"key":"10.1016\/j.jtha.2025.08.040_bib25","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1016\/j.ajhg.2020.02.010","article-title":"A Fast and Simple Method for Detecting Identity-by-Descent Segments in Large-Scale Data","volume":"106","author":"Zhou","year":"2020","journal-title":"Am J Hum Genet"},{"key":"10.1016\/j.jtha.2025.08.040_bib26","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.ajhg.2010.11.011","article-title":"GCTA: a tool for genome-wide complex trait analysis","volume":"88","author":"Yang","year":"2011","journal-title":"Am J Hum Genet"},{"key":"10.1016\/j.jtha.2025.08.040_bib27","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1016\/j.humimm.2013.06.025","article-title":"Six-locus high resolution HLA haplotype frequencies derived from mixed-resolution DNA typing for the entire US donor registry","volume":"74","author":"Gragert","year":"2013","journal-title":"Hum Immunol"},{"key":"10.1016\/j.jtha.2025.08.040_bib28","doi-asserted-by":"crossref","DOI":"10.1016\/j.rpth.2023.102265","article-title":"Inhibitor development according to concentrate in severe hemophilia: reporting on 1392 previously untreated patients from Europe and Canada","volume":"7","author":"Fischer","year":"2023","journal-title":"Res Pract Thromb Haemost"},{"key":"10.1016\/j.jtha.2025.08.040_bib29","doi-asserted-by":"crossref","first-page":"4648","DOI":"10.1182\/blood-2006-11-056291","article-title":"Treatment-related risk factors of inhibitor development in previously untreated patients with hemophilia A: the CANAL cohort study","volume":"109","author":"Gouw","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2025.08.040_bib30","doi-asserted-by":"crossref","DOI":"10.1016\/j.rpth.2022.100020","article-title":"clinical determinants of the Outcome of Immune Tolerance Induction study g. Determinants of successful immune tolerance induction in hemophilia A: systematic review and meta-analysis","volume":"7","author":"Oomen","year":"2023","journal-title":"Res Pract Thromb Haemost"},{"key":"10.1016\/j.jtha.2025.08.040_bib31","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1038\/nm.2942","article-title":"A bispecific antibody to factors IXa and X restores factor VIII hemostatic activity in a hemophilia A model","volume":"18","author":"Kitazawa","year":"2012","journal-title":"Nat Med"},{"key":"10.1016\/j.jtha.2025.08.040_bib32","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1056\/NEJMoa1803550","article-title":"Emicizumab prophylaxis in patients who have hemophilia A without inhibitors","volume":"379","author":"Mahlangu","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtha.2025.08.040_bib33","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1111\/hae.14398","article-title":"Low immunogenicity of emicizumab in persons with haemophilia A","volume":"27","author":"Schmitt","year":"2021","journal-title":"Haemophilia"},{"key":"10.1016\/j.jtha.2025.08.040_bib34","first-page":"1329","article-title":"Long-term outcomes with emicizumab prophylaxis for hemophilia A with or without FVIII inhibitors from the HAVEN 1-4 studies","volume":"142","author":"Callaghan","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2025.08.040_bib35","first-page":"290","article-title":"Factor VIII trafficking to CD4+ T cells shapes its immunogenicity and requires several types of antigen-presenting cells","volume":"142","author":"Kaczmarek","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2025.08.040_bib36","doi-asserted-by":"crossref","first-page":"4983","DOI":"10.1182\/bloodadvances.2021004909","article-title":"Anti-FVIII antibodies in Black and White hemophilia A subjects: do F8 haplotypes play a role?","volume":"7","author":"Pratt","year":"2023","journal-title":"Blood Adv"},{"key":"10.1016\/j.jtha.2025.08.040_bib37","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1182\/blood-2015-10-675512","article-title":"FVIII-binding IgG modulates FVIII half-life in patients with severe and moderate hemophilia A without inhibitors","volume":"128","author":"Hofbauer","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2025.08.040_bib38","doi-asserted-by":"crossref","first-page":"6140","DOI":"10.1182\/bloodadvances.2022007458","article-title":"Surgical outcomes in people with hemophilia A taking emicizumab prophylaxis: experience from the HAVEN 1-4 studies","volume":"6","author":"Kruse-Jarres","year":"2022","journal-title":"Blood Adv"},{"key":"10.1016\/j.jtha.2025.08.040_bib39","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1053\/j.seminhematol.2003.11.016","article-title":"Environmental and genetic factors influencing inhibitor development","volume":"41","author":"Oldenburg","year":"2004","journal-title":"Semin Hematol"},{"key":"10.1016\/j.jtha.2025.08.040_bib40","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1111\/j.1365-2516.2011.02509.x","article-title":"Assessing the impact of age, race, ethnicity and inhibitor status on functional limitations of patients with severe and moderately severe haemophilia A","volume":"17","author":"Leissinger","year":"2011","journal-title":"Haemophilia"},{"key":"10.1016\/j.jtha.2025.08.040_bib41","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1111\/j.1365-2516.2010.02429.x","article-title":"Immune tolerance induction in 31 children with haemophilia A: is ITI less successful in African Americans?","volume":"17","author":"Callaghan","year":"2011","journal-title":"Haemophilia"},{"key":"10.1016\/j.jtha.2025.08.040_bib42","doi-asserted-by":"crossref","first-page":"e260","DOI":"10.1111\/j.1365-2516.2011.02739.x","article-title":"Increased prevalence of inhibitors in Hispanic patients with severe haemophilia A enrolled in the Universal Data Collection database","volume":"18","author":"Carpenter","year":"2012","journal-title":"Haemophilia"},{"key":"10.1016\/j.jtha.2025.08.040_bib43","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1182\/blood-2014-09-599365","article-title":"Personalized Approaches to Therapies for Hemophilia Study I. Factor VIII gene variants and inhibitor risk in African American hemophilia A patients","volume":"126","author":"Gunasekera","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2025.08.040_bib44","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1182\/blood-2002-05-1369","article-title":"CD4+ T-cell clones specific for wild-type factor VIII: a molecular mechanism responsible for a higher incidence of inhibitor formation in mild\/moderate hemophilia A","volume":"101","author":"Jacquemin","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2025.08.040_bib45","doi-asserted-by":"crossref","first-page":"4073","DOI":"10.1182\/blood-2011-08-374645","article-title":"CD4+ T-cell epitopes associated with antibody responses after intravenously and subcutaneously applied human FVIII in humanized hemophilic E17 HLA-DRB1\u22171501 mice","volume":"119","author":"Steinitz","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2025.08.040_bib46","doi-asserted-by":"crossref","first-page":"2399","DOI":"10.1111\/j.1538-7836.2007.02762.x","article-title":"T-cell responses over time in a mild hemophilia A inhibitor subject: epitope identification and transient immunogenicity of the corresponding self-peptide","volume":"5","author":"James","year":"2007","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.jtha.2025.08.040_bib47","doi-asserted-by":"crossref","first-page":"2043","DOI":"10.1182\/blood-2015-11-682468","article-title":"T cells from hemophilia A subjects recognize the same HLA-restricted FVIII epitope with a narrow TCR repertoire","volume":"128","author":"Ettinger","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2025.08.040_bib48","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1128641","article-title":"Hemophilia A subjects with an intron-22 gene inversion mutation show CD4(+) T-effector responses to multiple epitopes in FVIII","volume":"14","author":"Gunasekera","year":"2023","journal-title":"Front Immunol"},{"key":"10.1016\/j.jtha.2025.08.040_bib49","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.3389\/fimmu.2020.01219","article-title":"Hemophilia A inhibitor subjects show unique PBMC gene expression profiles that include up-regulated innate immune modulators","volume":"11","author":"Karim","year":"2020","journal-title":"Front Immunol"},{"key":"10.1016\/j.jtha.2025.08.040_bib50","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1055\/s-0038-1655945","article-title":"HLA genotype of patients with severe haemophilia A due to intron 22 inversion with and without inhibitors of factor VIII","volume":"77","author":"Oldenburg","year":"1997","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.jtha.2025.08.040_bib51","doi-asserted-by":"crossref","first-page":"2006","DOI":"10.1111\/j.1538-7836.2009.03636.x","article-title":"Impact of polymorphisms of the major histocompatibility complex class II, interleukin-10, tumor necrosis factor-alpha and cytotoxic T-lymphocyte antigen-4 genes on inhibitor development in severe hemophilia A","volume":"7","author":"Pavlova","year":"2009","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.jtha.2025.08.040_bib52","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0080239","article-title":"Limited promiscuity of HLA-DRB1 presented peptides derived of blood coagulation factor VIII","volume":"8","author":"van Haren","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.jtha.2025.08.040_bib53","doi-asserted-by":"crossref","first-page":"108","DOI":"10.3109\/09273948.2011.559302","article-title":"An update on the genetics of HLA B27-associated acute anterior uveitis","volume":"19","author":"Martin","year":"2011","journal-title":"Ocul. Immunol. Inflamm."},{"key":"10.1016\/j.jtha.2025.08.040_bib54","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pgen.1009199","article-title":"Function of multiple sclerosis-protective HLA class I alleles revealed by genome-wide protein-quantitative trait loci mapping of interferon signalling","volume":"16","author":"Lundtoft","year":"2020","journal-title":"PLoS Genet"},{"key":"10.1016\/j.jtha.2025.08.040_bib55","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1007\/s11892-011-0223-x","article-title":"Genetics of the HLA region in the prediction of type 1 diabetes","volume":"11","author":"Noble","year":"2011","journal-title":"Curr Diab Rep"},{"key":"10.1016\/j.jtha.2025.08.040_bib56","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.54558","article-title":"Identifying the immune interactions underlying HLA class I disease associations","volume":"9","author":"Debebe","year":"2020","journal-title":"Elife"},{"key":"10.1016\/j.jtha.2025.08.040_bib57","doi-asserted-by":"crossref","first-page":"2351","DOI":"10.1182\/bloodadvances.2024012862","article-title":"Race and ethnicity reporting and representation in hemophilia clinical trials","volume":"8","author":"Fedewa","year":"2024","journal-title":"Blood Adv"}],"container-title":["Journal of Thrombosis and Haemostasis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1538783625006026?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1538783625006026?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T07:22:17Z","timestamp":1778224937000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1538783625006026"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":57,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["S1538783625006026"],"URL":"https:\/\/doi.org\/10.1016\/j.jtha.2025.08.040","relation":{},"ISSN":["1538-7836"],"issn-type":[{"value":"1538-7836","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Human leukocyte antigen alleles associated with inhibitor development in severe hemophilia A: analysis of the \u201cMy Life, Our Future\u201d hemophilia A cohort","name":"articletitle","label":"Article Title"},{"value":"Journal of Thrombosis and Haemostasis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtha.2025.08.040","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Inc. on behalf of International Society on Thrombosis and Haemostasis.","name":"copyright","label":"Copyright"}]}}